Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and challenges shaping SMMT's future.

Viking Therapeutics (VKTX 1.70%) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company ...

When surgeons dissect tissue to remove a tumor or make a repair, they must work cautiously, relying on electrophysical ...

Brazil is experiencing a regulatory revolution that is fundamentally transforming its medical device clinical trial landscape ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

New diagnostic tools detect diseases at earlier stages while helping doctors personalize treatments. Medical institutions support these breakthrough tests through rigorous clinical trials and ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...

Fifty-five percent of the studies demonstrated alternative endpoint ... The researchers suggest that late-phase clinical trial design should focus on OS and QoL improvements to obtain the most valid ...

Thermo Fisher Scientific’s Accelerator™ Drug Development solutions, which integrate services for contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs) ...

Panelists discuss how robust clinical evidence from major studies like the EPIC and OPERA trials demonstrates that ...

Objectives To analyse developments (and their causes) in the number and proportion of clinical trials that were registered in different parts of the world after the International Committee of Medical ...

Results The CO 2 e emissions generated by the trial were 17.65 tonnes. This is equivalent to the emissions generated by driving an average petrol-fueled family car 71 004 km or roughly 1.8 times ...